Verona Pharma Ensifentrine: A New Era In Respiratory Disease Treatment (NASDAQ:VRNA) seekingalpha.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from seekingalpha.com Daily Mail and Mail on Sunday newspapers.
- Completed successful PK/PD study for otenaproxesul’s new formulation
- Phase II initiation on track for upcoming quarter
- Ended quarter with $28 million in cash and equivalents
.
Verona Pharma plc (NASDAQ:VRNA) Q3 2023 Earnings Call Transcript November 4, 2023 Operator: Welcome to Verona Pharma’s Third Quarter 2023 Financial Results and Operating Highlights Conference Call. At this time, all participants are in a listen-only mode. [Operator Instructions] Earlier this morning, Verona Pharma issued a press release announcing its financial results for the three […]
Bavarian Nordic Announces First Half 2023 Results streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.
- Otenaproxesul new formulation tablets manufactured for upcoming PK/PD study
- PK/PD study results expected next quarter with Phase II initiation in calendar Q1 2024
- Ended quarter with $34.3. -Today at 07:03 am- MarketScreener